Dr Andre Choo leads the Antibody Discovery Platform at Bioprocessing Technology Institute (BTI) focusing on the discovery of new biologics against stem cells and cancer cells. He was also responsible for the discovery of a first-in-class antibody that kills embryonic stem cells and improves the safety of stem cell therapy. Apart from BTI, he holds a joint appointment with the Experimental Drug Discovery Centre (EDDC), where he is managing 2 mAb programs with the goal of clinical development and trials.
Conference 29 - 31 October • Exhibition & Seminars 29 - 31 October
To sponsor or exhibit contact:
Derek Cavanagh
+44 (0)207 092 1297
derek.cavanagh@terrapinn.com
To speak:
Joan Shutt
+44 (0)207 092 1134
joan.shutt@terrapinn.com